Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity

Fig. 6

CAR T cells traffic to the brainstem and extend survival without overt toxicity. (a) EGFRvIII-CAR transduction quantification using biotinylated protein L and streptavidin-PE staining. (b) VITAL assay of B16-EGFRvIII-specific killing over B16-parental cells by EGFRvIII-CAR T cells after 24 h. (n = 2) (c) Kaplan-Meier survival curve of B16-EGFRvIII brainstem tumors treated with 5Gy total body irradiation followed by EGFRvIII-CAR T cells or untransduced controls and anti-PD1 antibody or IgG control. (n = 8 mice/group) Figure is representative of two independent experiments. (d) Representative IVIS bioluminescent images of EGFRvIII-CAR-Luciferase treated mice. (e) Representative mice bearing B16-EGFRvIII brainstem tumors sacrificed for histologic analysis four days after GFP-tagged CAR administration. H&E (left, 20x) and anti-GFP (green)/DAPI(blue) (right, 40x) (f) Serial weight measurements from (c). (n = 8 mice/group)

Back to article page